RAFFA WEALTH MANAGEMENT, LLC’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$897 Hold
11
﹤0.01% 1052
2026
Q1
$749 Buy
11
+1
+10% +$71 ﹤0.01% 1008
2025
Q4
$760 Hold
10
﹤0.01% 984
2025
Q3
$614 Hold
10
﹤0.01% 1015
2025
Q2
$488 Hold
10
﹤0.01% 1000
2025
Q1
$510 Hold
10
﹤0.01% 956
2024
Q4
$451 Hold
10
﹤0.01% 1015
2024
Q3
$371 Hold
10
﹤0.01% 1017
2024
Q2
$306 Hold
10
﹤0.01% 1098
2024
Q1
$291 Hold
10
﹤0.01% 1083
2023
Q4
$276 Hold
10
﹤0.01% 1019
2023
Q3
$224 Hold
10
﹤0.01% 1020
2023
Q2
$407 Hold
10
﹤0.01% 990
2023
Q1
$484 Hold
10
﹤0.01% 975
2022
Q4
$382 Hold
10
﹤0.01% 987
2022
Q3
$502 Hold
10
﹤0.01% 1035
2022
Q2
$401 Hold
10
﹤0.01% 1060
2022
Q1
$373 Hold
10
﹤0.01% 1083
2021
Q4
$398 Hold
10
﹤0.01% 1086
2021
Q3
$372 Hold
10
﹤0.01% 1077
2021
Q2
$423 Sell
10
-9
-47% -$386 ﹤0.01% 1066
2021
Q1
$900 Buy
19
+10
+111% +$594 ﹤0.01% 865
2020
Q4
$549 Hold
9
﹤0.01% 855
2020
Q3
$421 Hold
9
﹤0.01% 834
2020
Q2
$457 Hold
9
﹤0.01% 834
2020
Q1
$401 Buy
+9
New +$453 ﹤0.01% 783

Other funds holding PTCT

RAFFA WEALTH MANAGEMENT, LLC's PTCT Position: Q2 2026 in Review

RAFFA WEALTH MANAGEMENT, LLC held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 11 shares worth $897. The position accounts for ﹤0.01% of the portfolio, ranked #1052.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in PTCT in Q1 2020 and has held it in 26 quarters since. The position peaked at $900 in Q1 2021. 73 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • RAFFA WEALTH MANAGEMENT, LLC held 11 shares of PTC Therapeutics worth $897 as of Q2 2026.
  • RAFFA WEALTH MANAGEMENT, LLC left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of RAFFA WEALTH MANAGEMENT, LLC's portfolio in Q2 2026, its #1052 holding.
  • RAFFA WEALTH MANAGEMENT, LLC first reported a position in PTC Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • RAFFA WEALTH MANAGEMENT, LLC's PTC Therapeutics position peaked at $900 in Q1 2021.
  • 73 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2026, filed 27 Jul 2026.